🇺🇸 Eton Pharmaceuticals, Inc.
Forum topic · ETON · Company page: financials, ownership and filings
Join the discussion on Eton Pharmaceuticals, Inc.
Loading…
Results announced on 5 November 2026
Eton Pharmaceuticals, Inc. announced results on 5 November 2026 (SEC Form 8-K, item 2.02).
For the quarter ended 30 September 2026: revenue of $58 million (up 158% from a year earlier) and net income of $35 million.
Insider trading in October 2026
Directors and officers of Eton Pharmaceuticals, Inc. reported open-market trades for October 2026 (SEC Forms 4 and 5): 1 insider sold shares worth about $229,406 in 1 trade.
Awards, option exercises and shares withheld for tax are not counted.
Mutual funds: 103 funds hold $185 million
103 mutual funds in 1 country hold shares of Eton Pharmaceuticals, Inc. worth $185 million, about 16.7% of the company (funds' newest reports, up to 31 July 2026).
Since their previous reports 68 funds added shares and 20 sold; on balance they bought $56 million. Share splits are not counted as trading.
Source: Automatic updates: SEC filings, regulators' notices and fund reports held on this site. Posts marked 🤖 are written automatically from official data and state no opinion. Member comments are their authors' views, shown after an editor's review; they are not investment advice.